B+
Bull case
15%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
YDES
Breeze AcquisitionFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
YD Bio has reported 17% FY2025 revenue growth, approximately $6.0 million of cash, expanded U.S. diagnostic access, and multiple planned regulatory milestones.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Coverage is low, analyst targets are unavailable, and the peer set is based mainly on same-sector market capitalization rather than direct operating comparability.
Momentum
66
Value
46
Sentiment
6
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.20 · Bull $3.50 · Bear $1.25Analysis 2026-07-23; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-23 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum66 · Δ7d -
Value46 · Δ7d 0.0
Sentiment6 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Coverage is low, analyst targets are unavailable, and the peer set is based mainly on same-sector market capitalization rather than direct operating comparability.
- • FY2025 net loss and operating expenses were substantial relative to approximately $6.0 million of reported cash; cash runway and financing needs are not sufficiently established.
- • FY2025 net loss was approximately $8.3 million, operating expenses rose to about $5.4 million, and the company reported lower gross margin from a less favorable product mix.
Catalyst clock
2026-07-23
Post-earnings verification remains unresolved
Lead driver: Value · See fundamentals
Momentum
66
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
46
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
6
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 66.3 / Value 46.5 / Sentiment 6.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-23. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$238.7M
Beta
-
Shares Out
70.83M
P/E (TTM) · Derived
-27.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-10.31
Rev YoY
-
EPS YoY
-116.0%
Gross Margin
-
Op Margin
-
Net Debt
-$6M
Current Ratio
0.02
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data